Suzhou HuiLiao Biomedical Technology Co., Ltd. (hereinafter referred to as 'Suzhou HuiLiao') was formally established in May 2021 in the 2.5 Industrial Park of Suzhou Industrial Park. It is a high-tech enterprise engaged in the industrialization of comprehensively providing nucleic acid drugs.

　　The company's business covers various fields such as mRNA drug R&D and production, clinical trial design, data analysis, etc., focusing on the development of infectious disease vaccines, tumor vaccines, cell therapy, protein replacement, etc. based on mRNA technology. Focusing on the new type of mRNA delivery preparation CLS system, the company is committed to developing an mRNA drug technology production platform with China's independent intellectual property rights.